This test is most useful if any of these apply to you.
Fever, chills, and aching muscles after time outdoors can come from Anaplasma phagocytophilum, a bacterium spread mainly by ticks. This screen looks for IgM antibodies that react with the bacterium. IgM is one class of antibody your immune system produces, but its presence doesn't reliably establish a recent infection.
The distinction matters when you're sick. An early infection can produce a negative antibody result, while a detected result can persist after an infection or reflect a reaction to another organism. Whole-blood PCR and paired IgG antibody testing are the more reliable tools for confirming anaplasmosis. PCR looks for the bacterium's genetic material.
The illness is called human granulocytic anaplasmosis, often shortened to HGA. In the United States, blacklegged and western blacklegged ticks spread it. Symptoms usually begin 5 to 14 days after an infected tick bites you, though many people never notice a bite. Low white blood cell and platelet counts are common, and liver enzymes often rise.
Most cases are mild or moderate, but severe illness can develop, especially when treatment is delayed or your immune system is weakened. Older adults are also at greater risk. Rare complications include muscle breakdown, kidney injury, and an extreme immune reaction that damages organs.
This is a serum antibody screen performed by indirect immunofluorescence, or IFA. Your serum is applied to a slide containing bacterial material. A fluorescent reagent reveals whether IgM antibodies have attached to that material.
The screen reports whether reactive IgM was detected. It doesn't report an antibody concentration or a bacterial count. A positive screen may be followed by a separate titer result. A titer is the highest dilution of the sample at which antibody binding is still detectable. The screen and the titer are different results.
IgM doesn't follow a dependable early-rise, quick-fall pattern in anaplasmosis. In a South Korean hospital study of 21 confirmed cases, about a third had detectable IgM at admission. By two weeks after symptoms began, about four in five were IgM-positive, and IgM stayed detectable in follow-up samples through six months. IgG rose faster than IgM, peaking around four weeks, while IgM peaked around three months.
Those findings came from serum IFA testing with a commercial antigen grown in one laboratory cell line, in a small group of hospitalized adults. The authors suggested the antigen may explain why their titers differed from US reports. The study explains why timing matters, but it isn't a universal accuracy estimate for every IgM screen. A detected IgM result cannot reliably date an infection.
Research using other antibody measurements shows the same early gap. In a study of 38 people whose infections were confirmed by both PCR and culture, about 55% had detectable antibodies at their first visit. All 16 initially antibody-negative participants with follow-up samples later developed detectable antibodies. That study used an assay detecting IgG, IgA, and IgM together, so its findings aren't an IgM-specific sensitivity estimate.
Direct detection methods also differ. In a study of 71 people with anaplasmosis, the subgroup of 55 who received all three direct tests had positive cultures in about 91% of cases. PCR detected about 82%, and examination of a blood smear detected about 64%. These results describe that study's methods and population. Culture requires specialized laboratories, while whole-blood PCR is the practical early diagnostic test.
Healthy people can also have reactive Anaplasma antibodies. The studies below used IgG or combined antibody assays, not this IgM screen. Their results show why symptoms and exposure matter; they do not measure this screen's false-positive rate.
| Who Was Studied | What Was Measured | What Was Found |
|---|---|---|
| 159 healthy adult blood donors in Westchester County, New York | Serum IFA detecting IgG, IgM, and IgA together | About 11% had reactive antibodies. |
| 301 healthy blood donors in western Norway | Serum IgG antibodies by IFA | About 16% had reactive IgG. |
| 90 adults followed after tick bites in Sweden and the Åland Islands | Changes in serum IgG antibodies | One person developed a fourfold antibody rise without symptoms; no clinical anaplasmosis was identified. |
In the New York study, the authors confirmed about a third of the reactive donor samples by immunoblot. They concluded that many adults without clinical disease test positive at the usual IFA cutoff.
A small European study found reactive Anaplasma IgM or IgG in some people with PCR-confirmed neoehrlichiosis. It examined serum and plasma, and most participants with confirmed neoehrlichiosis were immunocompromised. The authors offered three possible explanations: past Anaplasma exposure, coinfection, or cross-reacting antibodies. The findings do not establish how often this IgM screen cross-reacts.
The useful antibody comparison is a change in IgG titers between an early sample and a recovery sample. A substantial rise supports a recent infection. Repeating a qualitative IgM screen provides no numerical level to trend, and an unchanged detected result cannot distinguish persistent antibodies from ongoing infection. Antibody results also aren't a measure of how severe the illness is.
Evidence-backed interventions that affect your A. Phagocytophilum IgM Screen level
A. Phagocytophilum IgM Screen is best interpreted alongside these tests.
A. Phagocytophilum IgM Screen is included in these pre-built panels.
See whether a tick may have left you with anaplasmosis, and whether the exposure looks recent or long past.